<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03202368</url>
  </required_header>
  <id_info>
    <org_study_id>ML39425</org_study_id>
    <secondary_id>2016-002716-41</secondary_id>
    <nct_id>NCT03202368</nct_id>
  </id_info>
  <brief_title>An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)</brief_title>
  <official_title>An Extension Study to Evaluate Long Term Safety of Subcutaneous Tocilizumab in Patients With Giant Cell Arteritis Who Have Completed WA28119 Core Study in France, and Subsequently Having Flare or Persisting Disease Activity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, interventional, open-label, long-term extension study of Study WA28119&#xD;
      (NCT01791153) to evaluate the long-term safety of SC tocilizumab in participants with GCA who&#xD;
      subsequently have flare or persisting disease activity. A maximum of 11 participants from six&#xD;
      centers in France that participated in the WA28119 study will be enrolled. The entire study&#xD;
      duration is anticipated to be approximately 160 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 25, 2017</start_date>
  <completion_date type="Actual">August 21, 2019</completion_date>
  <primary_completion_date type="Actual">August 21, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with Adverse Events</measure>
    <time_frame>Baseline up to 160 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline up to 160 weeks</measure>
    <time_frame>Baseline (Week 0), Weeks 48, 96, 156</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment of Disease Activity Disease Activity, as Assessed Based on Visual Analogue Scale Score</measure>
    <time_frame>Baseline (Week 0), Weeks 48, 96, 156</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Erythrocyte Sedimentation Rate Values</measure>
    <time_frame>Baseline (Week 0), Weeks 48, 96, 156</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in C-Reactive Protein Values</measure>
    <time_frame>Baseline (Week 0), Weeks 48, 96, 156</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Receive Concomitant Medications With SC Tocilizumab</measure>
    <time_frame>Baseline up to 156 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of SC Tocilizumab Injections Administered</measure>
    <time_frame>Baseline up to 156 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total SC Tocilizumab Dose Administered</measure>
    <time_frame>Baseline up to 156 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of SC Tocilizumab Treatment</measure>
    <time_frame>Baseline up to 156 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of SC Tocilizumab Interruption</measure>
    <time_frame>Baseline up to 156 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration Between Last Tocilizumab Administration in Study WA28119 and First Tocilizumab Administration in Current Study</measure>
    <time_frame>From last tocilizumab administration in Study WA28119 to first tocilizumab administration in current study (approximately up to 3 years; assessed retrospectively at Baseline)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Giant Cell Arteritis</condition>
  <arm_group>
    <arm_group_label>Tocilizumab: GCA Flare or Persistent Disease Activity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who were treated with tocilizumab in Study WA28119 and experienced a new GCA flare within 3 years after completion of Study WA28119 or had persistent active GCA at the time of completion of Study WA28119, will receive SC tocilizumab in this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>162 milligrams (mg) of tocilizumab every week for a maximum of 156 weeks or until the commercial availability of tocilizumab, whichever comes first</description>
    <arm_group_label>Tocilizumab: GCA Flare or Persistent Disease Activity</arm_group_label>
    <other_name>RO4877533</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants who completed the 156-week WA28119 core study in France&#xD;
&#xD;
          -  Participants who experienced at any time during the WA28119 core study a clinical&#xD;
             improvement based on the Investigator's judgment and may continue to benefit from SC&#xD;
             tocilizumab in this study&#xD;
&#xD;
          -  Participants whom the investigator wants to treat with SC tocilizumab due to&#xD;
             persistent active GCA at the time of completion of the 156-week WA28119 core study&#xD;
             and/or new flare occurring within 3 years after completion of the 156-week WA28119&#xD;
             core study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who have prematurely withdrawn from the WA28119 core study for any reason&#xD;
&#xD;
          -  Participants who had major surgery within 8 weeks prior to screening or planned major&#xD;
             surgery within the next 12 months&#xD;
&#xD;
          -  Major ischemic event, unrelated to GCA, within 12 weeks of inclusion&#xD;
&#xD;
          -  Transplanted organs (except corneal transplant performed more than 3 months prior to&#xD;
             inclusion)&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to human, humanized, or murine&#xD;
             monoclonal antibodies or to prednisone&#xD;
&#xD;
          -  Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary&#xD;
             (including obstructive pulmonary disease), renal, hepatic, endocrine (including&#xD;
             uncontrolled diabetes mellitus), psychiatric, osteoporosis/osteomalacia, glaucoma,&#xD;
             corneal ulcers/injuries, or gastrointestinal (GI) disease&#xD;
&#xD;
          -  Current liver disease, as determined by the investigator (positive hepatitis B surface&#xD;
             antigen or hepatitis C antibody)&#xD;
&#xD;
          -  History of diverticulitis, diverticulosis requiring antibiotic treatment, or chronic&#xD;
             ulcerative lower GI disease such as Crohn's disease, ulcerative colitis, or other&#xD;
             symptomatic lower GI conditions that might predispose a participant to perforations&#xD;
&#xD;
          -  Known active current or history of recurrent bacterial, viral, fungal, mycobacterial,&#xD;
             or other infections (including but not limited to tuberculosis [TB] and atypical&#xD;
             mycobacterial disease, hepatitis B and C, and herpes zoster, but excluding fungal&#xD;
             infections of the nail beds)&#xD;
&#xD;
          -  Any major episode of infection requiring hospitalization or treatment with intravenous&#xD;
             (IV) antibiotics within 4 weeks of inclusion or oral antibiotics within 2 weeks of&#xD;
             inclusion&#xD;
&#xD;
          -  Active TB requiring treatment within the previous 3 years&#xD;
&#xD;
          -  Primary or secondary immunodeficiency (history of or currently active)&#xD;
&#xD;
          -  Evidence of malignant disease or malignancies diagnosed since last WA28119 study visit&#xD;
             (except basal and squamous cell carcinoma of the skin or carcinoma in situ of the&#xD;
             cervix uteri that have been excised and cured)&#xD;
&#xD;
          -  Female participants of childbearing potential and female participants who are&#xD;
             breastfeeding&#xD;
&#xD;
          -  Male participants of reproductive potential who are not willing to use an effective&#xD;
             method of contraception, such as condom, sterilization, or true abstinence throughout&#xD;
             study and for a minimum of 6 months after study drug therapy&#xD;
&#xD;
          -  History of alcohol, drug, or chemical abuse within 1 year prior to inclusion&#xD;
&#xD;
          -  Body weight of more than (&gt;) 150 kilograms&#xD;
&#xD;
          -  Treatment with any investigational agent within 12 weeks (or five half-lives of the&#xD;
             investigational drug, whichever is longer) of inclusion (except tocilizumab)&#xD;
&#xD;
          -  Previous treatment with cell-depleting therapies including investigational agents,&#xD;
             including but not limited to Campath (alemtuzumab), anti-cluster of differentiation&#xD;
             (CD) 4, anti-CD5, anti-CD3, anti-CD19, and anti-CD20&#xD;
&#xD;
          -  Treatment with IV gamma globulin or plasmapheresis within 6 months of inclusion&#xD;
&#xD;
          -  Previous treatment with alkylating agents such as chlorambucil or with total lymphoid&#xD;
             irradiation&#xD;
&#xD;
          -  Immunization with a live/attenuated vaccine within less than or equal to (â‰¤) 4 weeks&#xD;
             prior to inclusion&#xD;
&#xD;
          -  Treatment with hydroxychloroquine, cyclosporine A, azathioprine, or mycophenolate&#xD;
             mofetil within 4 weeks of inclusion&#xD;
&#xD;
          -  Treatment with etanercept within 2 weeks; infliximab, certolizumab, golimumab,&#xD;
             abatacept, or adalimumab within 8 weeks; or anakinra within 1 week of inclusion&#xD;
&#xD;
          -  Previous treatment with tofacitinib&#xD;
&#xD;
          -  Treatment with cyclophosphamide within 6 months of inclusion&#xD;
&#xD;
          -  Participants requiring systemic corticosteroids for other conditions other than GCA,&#xD;
             which, in the opinion of the Investigator, would interfere with the assessments of the&#xD;
             protocol&#xD;
&#xD;
          -  Receipt of more than (&gt;) 100 mg daily intravenous methylprednisolone within 6 weeks of&#xD;
             inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital La Cavale Blanche; Rhumatologie</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez; Internal Medicine</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Emile Muller; Medecine Interne</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 27, 2017</study_first_submitted>
  <study_first_submitted_qc>June 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Arteritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

